Skip to main content
Premium Trial:

Request an Annual Quote

Biosynex to Acquire ProciseDx

NEW YORK — ProciseDx said on Tuesday that it is being acquired by French diagnostics firm Biosynex for undisclosed terms.

ProciseDx has developed a point-of-care immunoassay platform that uses time-resolved measurement of fluorescence with fluorescence resonance energy transfer (TR-FRET) for therapeutic drug monitoring.

The San Diego-based firm has filed for US Food and Drug Administration clearance for two tests — Procise IFX, which measures infliximab (Janssen Biotech's Remicade) and Procise ADL, which measures adalimumab (AbbVie's Humira) — and expects to launch them later this year. Last year, ProciseDx received 510(k) clearance from the US Food and Drug Administration for its Procise CRP immunoassay for the quantitative determination of C-reactive protein in human serum.

"Biosynex has made point-of-care and therapeutic drug monitoring a strategic focus," Biosynex Deputy CEO Thierry Paper said in a statement. "We see many potential areas of expansion for the ProciseDx technology."

The deal for ProciseDx marks the latest in a number of deals that Biosynex has struck to expand its diagnostics footprint. It closed a $17.2 million buyout of infectious disease point-of-care testing firm Chembio Diagnostics in April. Biosynex also recently took a majority stake in France's Theradiag.